AnaptysBio (ANAB) Earning Somewhat Favorable Press Coverage, Report Shows

News stories about AnaptysBio (NASDAQ:ANAB) have trended somewhat positive recently, Accern reports. Accern scores the sentiment of press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. AnaptysBio earned a coverage optimism score of 0.16 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 46.2846011282619 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

These are some of the headlines that may have effected Accern Sentiment Analysis’s scoring:

A number of research analysts have recently weighed in on ANAB shares. Credit Suisse Group raised their price objective on shares of AnaptysBio from $34.00 to $38.00 and gave the stock an “outperform” rating in a research note on Friday, August 25th. Zacks Investment Research raised shares of AnaptysBio from a “hold” rating to a “buy” rating and set a $34.00 price objective for the company in a research note on Thursday, September 7th. Finally, Robert W. Baird started coverage on shares of AnaptysBio in a research note on Monday, July 10th. They issued an “outperform” rating and a $36.00 target price for the company. Six investment analysts have rated the stock with a buy rating, The company currently has an average rating of “Buy” and a consensus price target of $36.00.

Shares of AnaptysBio (NASDAQ:ANAB) opened at 32.35 on Tuesday. The stock’s market capitalization is $658.06 million. AnaptysBio has a 1-year low of $15.17 and a 1-year high of $33.58. The firm has a 50-day moving average of $24.56 and a 200 day moving average of $25.08.

AnaptysBio (NASDAQ:ANAB) last released its quarterly earnings results on Thursday, August 10th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.42) by $0.29. The firm had revenue of $7 million for the quarter, compared to analyst estimates of $3.45 million. On average, equities analysts anticipate that AnaptysBio will post ($1.96) earnings per share for the current fiscal year.

In other news, major shareholder Holdings A/S Novo sold 491,294 shares of the business’s stock in a transaction that occurred on Monday, August 7th. The shares were sold at an average price of $21.12, for a total transaction of $10,376,129.28. Following the sale, the insider now owns 2,952,527 shares in the company, valued at $62,357,370.24. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Ventures Vii L. P. Avalon sold 37,040 shares of the business’s stock in a transaction that occurred on Wednesday, July 26th. The shares were sold at an average price of $24.35, for a total transaction of $901,924.00. The disclosure for this sale can be found here. Insiders have sold 1,133,940 shares of company stock worth $24,223,316 in the last 90 days.

COPYRIGHT VIOLATION NOTICE: “AnaptysBio (ANAB) Earning Somewhat Favorable Press Coverage, Report Shows” was originally posted by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark and copyright law. The legal version of this piece of content can be accessed at https://sportsperspectives.com/2017/09/12/anaptysbio-anab-earning-somewhat-favorable-press-coverage-report-shows.html.

AnaptysBio Company Profile

AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.

Insider Buying and Selling by Quarter for AnaptysBio (NASDAQ:ANAB)

Receive News & Ratings for AnaptysBio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply